Medical Microinstruments raised $125M in a Series D announced October 8. BioStar Capital, already an investor, led the round. S3 Ventures and Angelini Ventures came in new, along with a strategic corporate investor the company did not name.
MMI sells Symani, a robot with wristed instruments sized for blood vessels, lymph channels and nerves. FDA authorized it through a De Novo in April 2024, five years after the CE mark. The company counts about 50 installed systems and roughly 3,500 microsurgical procedures worldwide.
The money goes to commercial expansion, energy instruments and digital surgery features. CEO Mark Toland said the company has proven there is demand for robotic microsurgery at leading institutions.
Founded in Pisa in 2015, MMI has now disclosed $336M across five rounds, $235M of it since 2024. Fifty installs against that much capital puts the weight on utilization, because microsurgery is a low-volume specialty and every placed system has to earn its keep in free flaps and lymphatic cases.